Standard versus Reduced-Dose Valganciclovir CMV Prophylaxis in High-Risk Liver Transplant Recipients

被引：0
|
作者：
Dann, J. [1 ]
Geyston, J. [1 ]
Majmundar, D. [1 ]
Haywood, S. [1 ]
Shoemaker, C. [1 ]
Pelletier, S. [1 ]
Wentworth, B. [1 ]
机构：
[1] UVA Univ Virginia Hlth, Charlottesville, VA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
120
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [1] Incidence of CMV Disease in High-Risk Liver Transplant Recipients on Low Dose Valganciclovir Prophylaxis
    Tischer, S.
    Park, J.
    Stuckey, L.
    Kaul, D.
    Sonnenday, C.
    Fontana, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 221 - 222
  • [2] Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Bixby, Alexandra L.
    Fitzgerald, Linda
    Park, Jeong M.
    Kaul, Daniel
    Tischer, Sarah
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
  • [3] Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Brady, R. L.
    Green, K.
    Frei, C.
    Maxwell, P.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (02) : 106 - 111
  • [4] Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high-risk abdominal transplant recipients
    Kreiser, Maura L. L.
    Dupuis, Robert
    Szempruch, Kristen R. R.
    Chargualaf, Laura M. M.
    CLINICAL TRANSPLANTATION, 2023, 37 (10)
  • [5] Effectiveness of Valganciclovir Cytomegalovirus Prophylaxis Protocol in High-Risk Liver Transplant Recipients
    Shivega, W. Gaya
    Samhan, Aya
    Bolognese, Alexandra
    Enestvedt, Kristian
    Maynard, Erin
    Orloff, Susan
    Scott, David
    Woodland, David
    Olyaei, Ali
    Connelly, Christopher
    AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (01) : S51 - S51
  • [6] Increased Incidence of Cytomegalovirus Infection in High-Risk Liver Transplant Recipients Receiving Valganciclovir Prophylaxis Versus Ganciclovir Prophylaxis
    Shiley, Kevin T.
    Gasink, Leanne B.
    Barton, Todd D.
    Pfeiffenberger, Patrice
    Olthoff, Kim M.
    Blumberg, Emily A.
    LIVER TRANSPLANTATION, 2009, 15 (08) : 963 - 967
  • [7] Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Taber, DJ
    Stone, SS
    Emovon, O
    Rogers, J
    Afzal, F
    Lin, A
    Rajagopalan, PR
    Baliga, PK
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 377A - 377A
  • [8] Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients
    Brueckner, A. J.
    Doligalski, C. T.
    Logan, A. T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S365 - S366
  • [9] Valganciclovir for CMV prophylaxis in liver transplant recipients: An initial experience.
    Berkman, SC
    Ashcraft, E
    Baillie, GM
    Taber, D
    Lin, A
    Rogers, J
    Baliga, P
    Chavin, KD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 358 - 358
  • [10] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Brueckner, A.
    Rumore, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S480 - S480
12345